Preview: Theriva Biologics's Earnings
Portfolio Pulse from Benzinga Insights
Theriva Biologics (AMEX:TOVX) is scheduled to release its quarterly earnings report on March 25, 2024, with analysts expecting an EPS of $-0.41. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat resulting in a 10.86% drop. Shares have decreased by 19.06% over the last year, indicating potential concern among long-term shareholders ahead of the earnings announcement.
March 22, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Theriva Biologics is expected to report an EPS of $-0.41 for the latest quarter, with a history of mixed stock price reactions to earnings announcements.
Given Theriva Biologics's history of mixed reactions to earnings reports and the current expectation of a negative EPS, the short-term impact on TOVX's stock price is uncertain. The company's past performance, including a significant drop after last quarter's earnings beat, suggests that investor reactions can be unpredictable. Additionally, the overall negative trend in the stock price over the past year may influence investor sentiment.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100